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Abstract
Adenosine A2A receptors (A2AR) are located postsynaptically in striatopallidal GABAergic neurons, antagonizing dopamine
D2 receptor functions, and are also located presynaptically at corticostriatal terminals, facilitating glutamate release. To
address the hypothesis that these two A2AR populations differently control the action of psychostimulants, we characterized
A2AR modulation of cocaine-induced effects at the level of DARPP-32 phosphorylation at Thr-34 and Thr-75, c-Fos
expression, and psychomotor activity using two lines of cell-type selective A2AR knockout (KO) mice with selective A2AR
deletion in GABAergic neurons (striatum-A2AR-KO mice), or with A2AR deletion in both striatal GABAergic neurons and
projecting cortical glutamatergic neurons (forebrain-A2AR-KO mice). We demonstrated that striatum-A2AR KO mice lacked
A2ARs exclusively in striatal GABAergic terminals whereas forebrain-A2AR KO mice lacked A2ARs in both striatal GABAergic
and glutamatergic terminals leading to a blunted A2AR-mediated facilitation of synaptosomal glutamate release. The
inactivation of A2ARs in GABAergic neurons reduced striatal DARPP-32 phosphorylation at Thr-34 and increased its
phosphorylation at Thr-75. Conversely, the additional deletion of corticostriatal glutamatergic A2ARs produced opposite
effects on DARPP-32 phosphorylation at Thr-34 and Thr-75. This distinct modulation of DARPP-32 phosphorylation was
associated with opposite responses to cocaine-induced striatal c-Fos expression and psychomotor activity in striatum-A2AR
KO (enhanced) and forebrain-A2AR KO mice (reduced). Thus, A2ARs in glutamatergic corticostriatal terminals and in
GABAergic striatal neurons modulate the action of psychostimulants and DARPP-32 phosphorylation in opposite ways. We
conclude that A2ARs in glutamatergic terminals prominently control the action of psychostimulants and define a novel
mechanism by which A2ARs fine-tune striatal activity by integrating GABAergic, dopaminergic and glutamatergic signaling.
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Introduction
Striatal circuits, composed mainly of GABAergic medium spiny
neurons (MSN), are the principal entry point of the basal ganglia
and the primary site for processing of motor, motivational and
cognitive behaviors [1]. MSN are driven by cortico-thalamic
excitatory glutamatergic projections and modulated by nigral
dopaminergic inputs. MSN project either directly (striatonigral
MSN) or indirectly (striatopallidal MSN) to output nuclei [2].
Adenosine A2A receptors (A2AR) are highly expressed in
striatopallidal MSN where they antagonize dopamine D2 receptor
(D2R) function [3]. In addition, A2AR are also located in striatal
glutamatergic terminals [4] where they are involved in the
modulation of glutamate release and corticostriatal synaptic
transmission [5,6,7,8]. Notably, blockade of A2AR in extra-striatal
forebrain neurons attenuates behavioral responses to psychostim-
ulants such as cocaine [9], amphetamine [10,11] or L-DOPA [12].
This led us to propose that presynaptic A2AR in corticostriatal
glutamatergic terminals exert their excitatory effects by facilitating
glutamate release to counteract the inhibitory effect of postsynaptic
A2AR in GABAergic MNS [3,9]. This working model places A2AR
in a unique position, integrating GABAergic, glutamatergic and
dopaminergic neurotransmission to fine-tune striatal activity.
Dopamine- and cAMP-regulated phosphoprotein (DARPP-32)
is a key signaling molecule coordinating MSN responsiveness,
where its activity is regulated by its phosphorylation status on
different residues, namely Thr-34 and Thr-75 [13]. The
phosphorylation of striatal DARPP-32 at Thr-34 and Thr-75 is
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under tight control of dopamine, adenosine and glutamatergic
signalling [13]. DARPP-32 phosphorylation at Thr-34 is con-
trolled by the Gs/Gi-cAMP-PKA signalling pathway via D1
receptors (D1R) in the direct pathway and A2AR/D2R activation
in the indirect pathway. DARPP-32 phosphorylation at Thr-75 in
MSN is competitively inhibited by and inversely correlated with
the activation of cAMP signalling and is additionally modulated by
glutamate signalling via cdk5 kinase [14]. Studies with global [13]
or striatal pathway-selective genetic deletion of DARPP-32
[15,16,17] confirmed that DARPP-32 activation in the direct
and indirect pathways oppositely determines motor responses to
psychoactive drugs. Specifically, the selective deletion of
DARPP32 in the indirect pathway enhances psychomotor activity
while the selective deletion of DARPP-32 in the direct pathway
attenuates the psychomotor effect [15,16]. Thus, Thr-34 and Thr-
75 phosphorylation of DARPP-32 integrates the glutamatergic
drive with dopaminergic extrinsic modulation as well as with
intrinsic striatal modulation such as through adenosine [13]. We
therefore hypothesize that A2AR in GABAergic and glutamatergic
neurons modulates the action of psychostimulants through a
putative opposite control of striatal DARPP-32 phosphorylation.
To test this hypothesis, we developed and characterized two cell
type-selective A2AR knockout (KO) lines with selective deletion of
A2AR either in inhibitory GABAergic striatopallidal neurons
(striatum-A2AR KO, st-A2AR KO) or in excitatory glutamatergic
cortical neurons in addition to GABAergic MSN (forebrain-A2AR
KO, fb-A2AR KO). Their use allowed us to demonstrate that
A2ARs in GABAergic MSN and in corticostriatal glutamatergic
terminals control the action of psychostimulants in opposite
manners at the levels of (i) DARPP-32 phosphorylation; (ii)
cocaine-induced c-Fos expression; and (iii) cocaine-induced
psychomotor activity. This suggests that A2AR control the action
of psychostimulants through the regulation of DARPP-32 phos-
phorylation (at Thr-34 and Thr-75) in striatopallidal neurons.
Furthermore, these results define a novel function of A2AR in
glutamatergic terminals and GABAergic striatopallidal neurons to
fine-tune striatal neuronal activity and the action of psychostim-
ulants through the integration of GABAergic, glutamatergic and
dopaminergic signaling pathways.
Results
1. Selective preservation of A2AR in glutamatergic but not
GABAergic terminals in striatum- (but not forebrain-)
A2AR KO mice
To demonstrate the selectivity of A2AR deletion in st-A2AR KO
and fb-A2AR KO mice, we quantified A2AR immunoreactivity in
glutamatergic (vesicular glutamate transporters type 1, vGluT1-
positive) and GABAergic (vesicular GABA transporters, vGAT-
positive) terminals from the striatum of st-A2AR KO, fb-A2AR KO
and global A2AR knockout (gb-A2AR KO) mice as well as their
corresponding wild-type (WT) littermates. Quantitative analysis
revealed that A2AR immunoreactivity was depleted in GABAergic
terminals from st-A2AR KO and fb-A2AR KO mice to background
levels (n = 4–6 animals per group, p,0.05, unpaired Student’s t
test) (Figure 1A) similar to these found in gb-A2AR KO mice (not
shown). In contrast, A2AR immunoreactivity in glutamatergic
terminals (about 50% of vGlut1-positive terminals contain A2AR,
see [7]) was completely abolished in fb-A2AR KO mice and gb-
A2AR KO mice (n = 4–6 animals per group, p,0.05, unpaired
Student’s t test), but was selectively preserved in st-A2AR KO mice
(n = 6, p.0.05, unpaired Student’s t test) due to the presence of
presynaptic A2AR on corticostriatal terminals of extra-striatal
glutamatergic neurons (Figure 1B). The preservation of presynap-
tic glutamatergic A2AR in st-A2AR KO mice was also consistent
with the normal level of A2AR binding density in total membranes
[9] and synaptosomal membranes (data not shown) of the cerebral
cortex of st-A2AR KO mice. Together, these data demonstrate
that A2AR in glutamatergic terminals of the striatum were
selectively preserved in st-A2AR KO mice but abolished in fb-
A2AR KO mice.
2. Selective preservation of the A2AR-mediated
facilitation of glutamate release in synaptosomes from
striatum-A2AR KO mice
To examine the functional consequence of A2AR deletion in
glutamatergic terminals in the striatum, we compared the ability of
the selective A2AR agonist CGS21680 to facilitate glutamate
release from striatal synaptosomes of fb-A2AR KO or st-A2AR KO
mice. In the absence of CGS21680, the elevation of extracellular
K+ concentration induced similar spike releases of glutamate from
striatal synaptosomes from WT mice during two consecutive
stimulation periods (ratio of 0.98 6 0.02, n = 16). A supra-
maximal but A2AR-selective concentration of CGS21680 (20 nM,
present during the second period of stimulation) enhanced 3H-
glutamate release by 38.2 6 2.4% and 35.9 6 1.9% from striatal
synaptosomes of fb-WT and st-WT mice, respectively (n = 6-8,
p,0.05 compared to 0%, one sample t-test) (Figure 2A and 2B). In
contrast, CGS21680-mediated facilitation of 3H-glutamate release
was completely abolished in striatal synaptosomes from fb-A2AR
KO mice (n = 4, p.0.05 compared to 0%) (Figure 2C), but was
unaffected in synaptosomes from st-A2AR KO mice (n = 4, p,0.
05 compared to 0%) (Figure 2D). These findings support the
selective preservation of presynaptic A2AR function in glutama-
tergic terminals in st-A2AR KO but not fb-A2AR KO mice.
3. A2AR in glutamatergic terminals and GABAergic
neurons oppositely modulate striatal DARPP-32
phosphorylation at Thr-34 and Thr-75
To determine the functional significance of the deletion of A2AR
exclusively in GABAergic striatal neurons (in st-A2AR KO) and of
its additional deletion in glutamatergic terminals (fb-A2AR KO),
we evaluated the phosphorylation status of striatal DARPP-32 at
Thr-34 in fb-A2AR KO mice (two-way ANOVA, drug effect:
F(1,12) = 95.765, p,0.001; genotype effect: F(1,12) = 7.753,
p = 0.017; drug x genotype: F(1,12) = 9.034, p = 0.011) (Figure
3A, 3B) and in st-A2AR KO mice (two-way ANOVA, drug effect:
F(1,20) = 78.861, p,0.001; genotype effect: F(1,20) = 25.924,
p,0.001; drug x genotype: F(1,20) = 12.508, p= 0.002) (Figure
3C, 3D). In addition, we also evaluated the phosphorylation status
of striatal DARPP-32 at Thr-75 in fb-A2AR KO mice (two-way
ANOVA, drug effect: F(1,12) = 78.577, p,0.001; genotype effect:
F(1,12) = 0.600, p = 0.454; drug x genotype: F(1,12) = 0.717,
p = 0.414) (Figure 3E, 3F) as well as in st-A2AR KO mice
(two-way ANOVA, drug effect: F(1,12) = 624.116, p,0.001;
genotype effect: F(1,12) = 42.378, p,0.001; drug x genotype:
F(1,12) = 16.111, p = 0.002) (Figure 3G, 3H). Under basal
condition (i.e. after treatment with vehicle), the level of DARPP-
32 phosphorylation at Thr-75 or at Thr-34 was comparable
between fb-A2AR KO mice and their fb-WT littermates (Figure 3B
and 3F) (n = -4-6 per group, p.0.05, two-way ANOVA post hoc
Bonferroni test). Interestingly, the deletion of A2AR in GABAergic
striatopallidal neurons significantly increased the basal level of
DARPP-32 phosphorylation at Thr-75 (Figure 3H) (n = 4 per
group, p,0.05) together with a (mild) reduction of the basal level
of DARPP-32 phosphorylation at Thr-34 (Figure 3D) in st-A2AR
KO (but not fb-A2AR KO) mice (n = 6). These observations are
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Figure 1. Deletion of A2AR immunoreactivity in glutamatergic terminals of forebrain-A2AR KO and GABAergic terminals of both
forebrain A2AR - and striatum-A2AR KO mice. Detection and quantification of the percentage of GABAergic terminals (A, vGAT-positive) and
glutamatergic terminals (B, vGluT1-positive) and from forebrain-selective-A2AR KO (fb-KO) or striatum-selective-A2AR KO (st-KO) mice and their wild
type (WT) littermates (control) that are endowed with A2AR immunoreactivity. The bar graphs represent the percentage of vGluT1- or vGAT-
immunopositive terminals that are also endowed with A2AR immunoreactivity (mean 6 SEM, 3 fields per mouse, n = 4-6 animal per group). * p,0.05
A2AR Action in Glutamatergic and GABAergic Neurons
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consistent with a direct effect of postsynaptic A2AR in GABAergic
neurons [18,19]. Also in agreement with previous studies [18,20],
acute treatment with cocaine (25 mg/kg, i.p.) produced a marked
increase of DARPP-32 phosphorylation at Thr-34 and a
concomitant reduction of DARPP-32 phosphorylation at Thr-75
in WT mice (st-WT and fb-WT, Figure 3). As predicted from a
direct, postsynaptic facilitatory effect of A2AR in GABAergic
neurons, cocaine-induced DARPP-32 phosphorylation at Thr-34
was significantly attenuated in st-A2AR KO mice compared to
their WT littermates (n = 6 per group, p,0.05 comparing cocaine
with saline treatment) (Figure 3D). In contrast, the acute treatment
with cocaine markedly increased DARPP-32 phosphorylation at
Thr-34 in fb-A2AR KO mice compared to WT littermates (n = 4,
p,0.05 comparing cocaine with saline treatment) (Figure 3A and
3B), consistent with a reduced glutamate release and dis-inhibition
of glutamate suppression of DARPP-32 phosphorylation at Thr-34
in fb-A2AR KO mice [14]. Additional fluorescence immunohis-
tochemistry using brain sections showed that DARPP32 phos-
phorylation at Thr-75 was markedly reduced 45 minutes after
cocaine treatment in fb-WT and fb-A2AR KO mice (data not
shown), a finding consistent with Western blot analysis. These
findings demonstrated that, following cocaine treatment, presyn-
aptic A2AR in glutamatergic terminals exert an opposite and
predominant effect over postsynaptic A2AR in GABAergic neurons
on striatal DARPP-32 phosphorylation at Thr-34 and Thr-75.
4. Cocaine-induced striatal c-Fos expression and
psychomotor activity are enhanced in striatum-A2AR KO
but attenuated in forebrain-A2AR KO mice
To evaluate the functional significance of the opposite
modulation of striatal DARPP-32 phosphorylation by A2AR in
GABAergic striatal neurons and in glutamatergic terminals, we
compared cocaine-induced psychomotor activity and c-Fos
expression, a measure of MSN activity, in the striatum of st-
A2AR KO and fb-A2AR KO mice. Consistent with our previous
reports [9], we found that cocaine (25 mg/kg, i.p.)-induced
psychomotor activity was enhanced in st-A2AR KO (n= 9) but
attenuated in fb-A2AR KO mice (n = 12) compared to their WT
littermates (n = 8-12) (two-way ANOVA, drug effect: F(1,24) =
91.892, p,0.001; genotype effect: F(3,24) = 8.456, p,0.001; drug
x genotype: F(3,24) = 13.297, p,0.001) (Figure 4A and 4B). The
vs corresponding WT littermates, using an unpaired Student’s t test. On the left side of each bar graph are shown representative
immunocytochemistry photographs displaying the superimposed immunoreactivities of vGluT1 or vGAT (green) and of A2AR (red).
doi:10.1371/journal.pone.0080902.g001
Figure 2. A2AR-mediated facilitation of
3H-glutamate release from striatal synaptosomes is abolished in forebrain-A2AR KO but
preserved in striatum-A2AR KO mice. The A2AR selective agonist, CGS21680 (20 nM) facilitated the evoked
3H-glutamate release from striatal
synaptosomes of fb-A2AR WT (n= 6, A), st-A2AR WT (n = 8, B) and st-A2AR KO (n= 4, D) but not fb-A2AR KO (n= 4, C). Each graph depicts the time
course of tritium release enhanced by 20 mM K+ (evoked release, applied twice) in the absence (black symbols and lines) or presence of 20 nM
CGS21680 (grey symbols and lines), as indicated by the horizontal lines. Indicates a significant (p,0.05, using a one-sample t-test against the
hypothetical value of 0%) CGS21680-induced facilitation and the mean 6 SEM facilitation is also indicated.
doi:10.1371/journal.pone.0080902.g002
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opposite psychomotor effects of cocaine in st-A2AR KO and fb-
A2AR KO mice were also paralleled by similar opposite effects of
cocaine on c-Fos gene expression in the striatum of these two
transgenic mouse strains. As expected, cocaine treatment (25 mg/
kg, i.p.) increased c-Fos expression in the striatum of WT mice (st-
WT and fb-WT, Figure 4C) to a similar extent. Interestingly,
cocaine-induced striatal c-Fos expression was enhanced in st-A2AR
KO mice (p,0.05, Student’s t-test, comparing with st-WT) (Figure
4C) but reduced in fb-A2AR KO mice compared to their
corresponding WT littermates (p,0.05, Student’s t-test, compar-
ing with fb-WT mice) (Figure 4C). Furthermore, double immu-
nohistochemical analysis showed that the cocaine-induced increase
of striatal c-Fos immunoreactivity in st-A2AR KO mice was
restricted to dynorphin-positive cells (Figure 4D). As shown in
Figure 3. Cocaine-induced phosphorylation of striatal DARPP-32 at Thr-34 and Thr-75 are oppositely affected in striatum-A2AR KO
and forebrain-A2AR KO mice. Western blot analysis of phosphorylated (p-Thr-34 and p-Thr-75) and total DARPP-32. Representative Western blots
of striatal protein extracts from fb-A2AR KO and fb-WT (A and E), st-A2AR KO or st-WT mice (C and F). The levels of DARPP-32 phosphorylation
(normalized with total DARPP-32 level) are shown as mean 6 SEM and presented as percentage of the value for saline-treated WT mice, for p-Thr-34
DARPP-32 levels in fb-A2AR KO (n= 4, B) and st-A2AR KO (n= 6, D) and p-Thr-75 DARPP-32 levels in fb-A2AR KO (n= 4, F) and st-A2AR KO (n= 6, H). #
p,0.05 comparing cocaine with saline treatment within same genotype, two-way ANOVA and a post hoc Bonferroni test; * p,0.05 comparing fb-
A2AR KO or st-A2AR KO with their corresponding WT littermates with same treatment, two-way ANOVA post hoc Bonferroni test.
doi:10.1371/journal.pone.0080902.g003
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Figure 4D, the majority of c-Fos-positive cells (black arrows) in the
striatum were also stained with dynorphin, whereas some neurons
were stained with dynorphin (white arrow heads) or c-Fos (black
arrow heads) only.
Lastly, we performed double fluorescence immunohistochemis-
try to investigate if the cocaine-induced c-Fos expression mostly
occurred in enkephalin (Enk)-positive or Enk-negative cells in fb-
A2AR KO mice. The basal level of c-Fos expression in fb-A2AR
KO mice was comparable with their WT littermates after saline
injection (Figure 5, A and B), while enkephalin-positive cells
constituted about 50% of the total cell population. Cocaine
treatment markedly increased striatal c-Fos expression in fb-WT
and fb-A2AR KO mice (two-way ANOVA, drug effect: F(1,34) =
234.289, p,0.001; genotype effect: F(1,34) = 70.643, p,0.001;
drug x genotype: F(1,34) = 56.521, p,0.001) (Figure 5, A and B).
This induction largely occurs in Enk-negative cells (drug effect:
F(1,34) = 202.149, p,0.001; genotype effect: F(1,34) = 33.480,
p,0.001; drug x genotype: F(1,34) = 21.888, p,0.001) (i.e. in the
direct pathway, Figure 5D); this finding is consistent with our
results using two color, sequential immunohistochemistry of c-Fos
and dynorphin (Figure 4) and also agrees with previous reports
that cocaine induces c-Fos expression predominantly in the D1R-
containing striatonigral neurons (e.g. [17]). In fb-WT animals, we
also observed a cocaine-induced c-Fos expression in the D2R-
containing indirect pathway, likely attributed to a postsynaptic
(striatopallidal) A2AR effect since cocaine-induced c-Fos expression
was reduced in fb-A2AR KO mice (Figure 5C). Thus fb-A2AR KO
mice displayed a reduced cocaine-induced c-Fos expression in the
direct pathway as well as the indirect pathway, although the
majority of cocaine-induced modifications of c-Fos expression in
fb-A2AR KO mice were attributed to the direct pathway (see
Figure 5). This finding suggests that the elimination of presynaptic
glutamatergic A2AR mainly affects the direct pathway to control
psychomotor activity and c-Fos expression.
Figure 4. Cocaine-induced psychomotor activity and striatal c-Fos expression were attenuated in forebrain-A2AR KO but enhanced
in striatal-A2AR KO mice. Ambulation was recorded for 180 min after injection of a single dose of cocaine (25 mg/kg, i.p.) or vehicle in fb-A2AR KO
(n = 12, A) and in st-A2AR KO (n= 9, B) mice and their WT littermates (n = 8–12). The arrow indicates the time of injection and the data are mean 6
SEM; *p,0.05, comparing fb-A2AR KO and st-A2AR KO groups to their corresponding WT group using two-way ANOVA and a post hoc Bonferroni test.
(C) Cocaine-induced c-Fos expression in the striatum of fb-A2AR KO (n= 12) and st-A2AR KO (n= 9) and their corresponding WT littermates (n = 8–12)
#
p,0.05, comparing to corresponding wild-types with cocaine treatment, two-way ANOVA post hoc Bonferroni test. (D) Representative co-
immunostaining of c-Fos with dynorphin. Black arrows indicate neurons co-stained with dynorphin and c-Fos; white arrow heads indicate neurons
stained with dynorphin only (greyish brown) and black arrow heads indicate neurons stained with c-Fos (reddish brown). Scale bar = 25 mm.
doi:10.1371/journal.pone.0080902.g004
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Discussion
A2AR in glutamatergic corticostriatal terminals modulate
psychomotor activity
Postsynaptic A2AR in GABAergic striatapallidal neurons are
involved in the modulation of motor activity due to the
concentrated expression of A2AR in striatopallidal neurons and
their antagonistic interactions with D2R [21]. In addition, A2AR
are also present and functional in presynaptic glutamatergic
terminals that play a primordial role in driving striatal circuits
[4,5,6,8,22]; however their role in the control of the action of
psychostimulants remains largely unexplored, due to the low
expression of the A2AR in the cerebral cortex and the inability to
selectively manipulate A2AR in distinct cellular elements. Further-
more, it is currently unknown if the presynaptic A2AR might
differentially affect the direct versus indirect pathways. The
comparative analysis of the phenotypes of st-A2AR KO and fb-
A2AR KO mice allowed us to dissect the effects of A2AR in
glutamatergic terminals from those of A2AR in GABAergic
striatopallidal neurons. Our main findings demonstrate that
presynaptic A2AR in corticostriatal glutamatergic terminals
facilitate glutamate release (by its presynaptic action alone or in
combination with the action of postsynaptic A2AR) and play a
predominant role in the control of DARPP-32 phosphorylation,
striatal c-Fos expression, and consequent enhanced psychomotor
activity upon cocaine exposure. Specifically, we showed that, in
contrast to st-A2AR KO, fb-KO mice display a markedly reduced
cocaine-induced c-Fos expression mainly in the MSN of the direct
but also of the indirect pathway. Together with the finding that the
deletion of A2AR in glutamatergic terminals in fb-A2AR KO
abolished the A2AR-mediated enhancement of glutamate release,
these results suggest that presynaptic A2AR control glutamate
release, affecting the activity of both the direct and indirect
pathways (with c-Fos expression as a marker for neuronal activity).
This indicates that forebrain A2AR exert their control of cocaine
action predominantly through the regulation of glutamate release,
which challenges previous views attributing those actions to the
control of the responsiveness of striatal GABAergic neurons. The
most intriguing aspect of A2AR function in glutamatergic terminals
is their ability to over-ride the effect of A2AR in striatopallidal
neurons, which have a nearly 20-fold higher A2AR density [3].
This preferential engagement of A2AR in glutamatergic terminals
is heralded by the observations that psychostimulants
[23,24,25,26] as well as NMDA receptor activation [27,28] can
enhance the local striatal extracellular levels of adenosine,
preferentially near glutamatergic but not GABAergic terminals
[25]. Thus, the pattern of generation of adenosine by psychostim-
Figure 5. Immunofluorescence double staining of c-Fos and enkephalin in forebrain-WT and forebrain-A2AR KO mice after saline or
cocaine treatment. (A) Representative merged images of immunofluorescence double staining of c-Fos (red) with enkephalin (Enk, green) in
cocaine- vs. saline-treated fb-A2AR KO and fb-WT mice. (B) Quantitative analysis demonstrating the percentage of total c-Fos positive [c-Fos
(+)]cells
out of the total cells. (C) Quantitative analysis showing the percentage of c-Fos and Enk double positive [c-Fos(+)Enk(+)] stained cells out of the total
cells. (D) Quantitative analysis demonstrating the percentage of c-Fos positive but Enk negative [c-Fos(+)Enk(2)] cells out of the total cells. Data in the
bar graphs are mean 6 SEM, n = 6-10 per group. * p, 0.05, vs. groups of same genotype with saline treatment; # p, 0.05 vs. cocaine-treated WT
groups. g p, 0.05, vs. saline-treated fb-A2AR group. Scale bar = 50 mm. Yellow arrows indicate neurons with c-Fos positive but Enk negative [c-
Fos(+)Enk(2)] staining; Red arrows indicate neurons with c-Fos and Enk double positive [c-Fos(+)Enk(+)] staining.
doi:10.1371/journal.pone.0080902.g005
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ulants may favor a preferential activation of presynaptic A2AR in
corticostriatal terminals.
A2AR in glutamatergic terminals and GABAergic neurons
of the indirect pathway differentially modulate the action
of psychostimulants through opposite control of DARPP-
32 phosphorylation
Our current findings mechanistically dissociate the role of A2AR
in glutamatergic terminals and in GABAergic neurons controlling
DARPP-32 phosphorylation in the indirect pathway. Strikingly,
the two different subsets of A2AR modulate the actions of
psychostimulants via DARPP-32 phosphorylation in an opposite
manner. In parallel with enhanced cocaine-induced c-Fos
expression and psychomotor activity, the selective inactivation of
A2AR in striatal GABAergic neurons (in st-A2AR KO mice)
reduced DARPP-32 phosphorylation at Thr-34 and enhanced
DARPP-32 phosphorylation at Thr-75. This modulation is
consistent with a direct effect of A2AR on GABAergic striatopalli-
dal neurons, since the inactivation of A2AR in GABAergic neurons
reduces protein kinase A activity and in turn reduces DARPP-32
phosphorylation at Thr-34, with a parallel increase of DARPP-32
phosphorylation at Thr-75 [19,29]. Furthermore, the increase of
DARPP-32 phosphorylation at Thr-34 in fb-A2AR KO mice is
best explained by the selective changes of DARPP-32 in the
indirect pathway since the attenuation of cocaine-psychomotor
activity is strongly correlated with enhanced DARPP-32 in the
indirect pathway (not the direct pathway) as clearly demonstrated
by the elegant work using cell-type specific DARPP-32 KO
[15,16]. Our findings are also in line with the concept that the
striatopallidal pathway exerts a general inhibitory effect on
behavior such as instrumental learning [30], psychostimulant
activity [9], and aversive behavior [31], as revealed by selective
destruction of the indirect pathway using targeted toxin expression
[32] and by optogenetic silencing [33,34].
However, the A2AR control of c-Fos expression in the striatum
seems to result mainly from the c-Fos response in the direct
pathway since we now demonstrated that cocaine-induced c-Fos
expression was detected mainly in dynorphin-positive neurons.
This effect could either result from recurrent collateral connections
between striatopallidal and striatonigral MSN [35] or from an
enhanced D2R-mediated release of endocannabinoids, which
would decrease glutamate release from corticostriatal terminals
projecting to both the indirect as well as the direct pathway [36].
This also explains the ability of A2AR to control D1R-mediated
responses such as rotational behavior [37,38], c-Fos expression in
striatopallidal neurons [39] and DARPP-32 phosphorylation
[29,40]. In addition, the c-Fos expression may also be a secondary
functional consequence of the enhanced psychomotor activity by
selective deletion of A2AR in the indirect pathway. Although only
derived from the use of a single dose of cocaine at single time
point, the present findings nonetheless provide an important
snapshot of the A2AR modulation of cocaine-induced molecular
responses at the level of DARPP-32 phosphorylation and c-Fos
expression in the striatum.
The additional elimination of A2AR from glutamatergic
terminals in fb-A2AR KO mice reduced the basal Thr-75
phosphorylation of DARPP-32 and caused an enhancement of
cocaine-induced Thr-34 phosphorylation of DARPP-32, in
contrast to our findings in st-A2AR KO mice. This suggests that
tonic activation of A2AR in glutamatergic corticostriatal terminals
exerts opposite effects (compared to A2AR in GABAergic
striatopallidal neurons) on striatal DARPP-32 phosphorylation.
Since the major biochemical and neurochemical differences
between fb-A2ARKO and st-A2AR KO mice is the deletion of
A2AR in glutamatergic terminals (Figure 1) and the consequent
abolishment of A2AR-facilitated glutamate release from striatal
nerve terminals (Figure 2), the different regulation of DARPP-32
phosphorylation by A2AR in fb-A2AR KO mice likely results either
from the impact of presynaptic A2AR on glutamate release alone
or from the combined effect of presynaptic A2AR and postsynaptic
A2AR actions, an issue that will require the use of selective
deletions of A2AR in presynaptic glutamatergic corticostriatal
terminals to be resolved. In fact, we are concluding that the
differences between the phenotypes of fb-A2AR KO and st-A2AR
KO mice are mostly due to the effects of presynaptic A2AR in
glutamatergic corticostriatal terminals since the most evident
differentiating factor in fb-A2AR KO mice is the deletion of
presynaptic A2AR and the abolishment of A2AR-mediated
facilitation of glutamate release. Since increased DARPP-32
phosphorylation at Thr-34 in the direct pathway is expected to
produce enhanced cocaine psychomotor activity [15,17], the
increased DARPP-32 phosphorylation at Thr-34, together with
the attenuation of cocaine-induced psychomotor activity in fb-
A2AR KO mice strongly suggests that glutamate release by A2AR
in corticostriatal terminals preferentially affects DARPP-32
phosphorylation in the indirect pathway. Conversely, fb-A2AR
KO mice display an altered c-Fos expression in the direct and
indirect pathways with the direct pathway being prominent one.
Overall, the molecular and behavioral responses found in fb-A2AR
KO mice suggest a selective modification of DARPP-32
phosphorylation in the indirect pathway and a prominent
modification of cocaine-induced c-Fos expression in the direct
pathway in tight correlation with cocaine-induced psychomotor
activity. This is in line with the findings from cell-type specific
deletion of DARPP-32, which showed that cocaine-induced
psychomotor activity was attenuated by selective inactivation of
DARPP-32 in the direct pathway [15]. While these results suggest
that A2AR activity in glutamatergic terminals and GABAergic
neurons may influence the action of psychostimulants by
controlling DARPP-32 phosphorylation selectively in the indirect
pathway, with the c-Fos response being secondary to the
psychomotor effect, additional experiments are clearly warranted
to clarify the cellular substrate linking the presynaptic A2AR
control of glutamate release and its impact on psychomotor
activity.
Neurobiological and therapeutic implications
Based on the opposite phenotypes of cocaine-induced molecular
and behavioral changes in st-A2AR KO and fb-A2AR KO mice,
and their association with glutamatergic, GABAergic and dopa-
minergic systems at presynaptic and postsynaptic sites, we propose
a new model for A2AR function in the control of striatal circuits:
A2AR in glutamatergic terminals and GABAergic neurons provide
a ‘‘fine-tuning’’ mechanism, whereby they integrate and regulate
dopaminergic and glutamatergic signaling in the striatum. The
integrated function of A2AR is accomplished through the opposing
actions of A2AR in GABAergic striatal neurons (through A2AR-
D2R antagonistic interactions) and in glutamatergic corticostriatal
terminals (by modulating glutamate release). The novelty of this
model is that the ‘‘fine-tuning’’ provided by A2AR may serve to
prevent over- or under-stimulation of striatal neurons, and
illustrates an essential aspect of the integrated function of the
adenosine neuromodulation system [41]. Since decreased gluta-
matergic neurotransmission and increased dopaminergic activity
contribute to the pathophysiology of schizophrenia and related
psychiatric disorders, the ability of A2AR to integrate dopaminer-
gic and glutamatergic systems indicates that adenosine acting at
A2AR Action in Glutamatergic and GABAergic Neurons
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e80902
A2AR may modulate both positive (by preventing hyper-dopami-
nergic activity) and negative (by preventing hypo-glutamatergic
activity) symptoms of schizophrenia [42]. Thus, the selective
manipulation of presynaptic A2AR in glutamatergic terminals [43]
may have a therapeutic value to manage a variety of neuropsy-
chiatric behaviors such as anxiety, depression, psychosis and
schizophrenia [44].
Materials and Methods
1. Generation and genotyping of striatum-A2AR KO mice
and forebrain-A2AR KO mice
Animals were handled according to the NIH Guide for the Care
and Use of Laboratory Animals and in accordance with the
protocol approved by the IACUC at the Boston University School
of Medicine and by the Faculty of Medicine of the University of
Coimbra. The Cre-loxP strategy was used to generate fb-A2AR
KO and st-A2AR KO mice. The generation and genotyping of fb-
A2AR KO mice has been described recently [10]. Briefly,
transgenic mice expressing the Cre recombinase under control
of the CaMKIIa gene promoter were crossbred with homozygous
floxed (A2AR
flox+/+) mice (F10 generation in congenic C57BL/6
background). Their Cre (+) A2AR flox+/+ offspring display an A2AR
deletion in postnatal forebrain neurons (including cortex, hippo-
campus and striatum). Similarly, homozygous floxed (A2AR
flox+/+)
mice (F5 generation in mixed 129-Steel and C57BL/6 back-
ground) were crossbred with Dlx5/6-Cre transgenic mice
expressing Cre recombinase under control of the Dlx5/6 gene
promoter, which is active exclusively in striatal neurons during
development [45,46,47], to generate st-A2AR KO mice [Dlx5/6-
Cre(+)A2ARflox+/+] mice [9]. Genotyping was conducted by 3
primer PCR analysis of tail DNA [10]. Fb-A2AR KO and st-A2AR
KO mice were characterized for their selective Adora2a deletion in
the forebrain (i.e., cortex, hippocampus, and striatum) [10,48] or
exclusively in striatal [9] neurons, as shown in our previous studies.
The selectivity in these two lines was further validated by Cre-
expression by X-gal staining of LacZ in a Rosa26 reporter
transgenic line, PCR analysis of Cre-mediated Adora2a deletion,
A2AR immunohistochemistry and
3H-ZM241385 radioligand
binding of A2AR density [9,10,48,49]. Our early studies showed
that the behaviors of two WT genotypes [Cre(–)A2AR
flox+/+ or
Cre(+)A2ARflox2/2] were not distinguishable (data not shown) and
so we used either WT type or in some cases two WT types were
pooled in to one group referred to as simply st-WT or fb-WT,
accordingly.
2. Drug treatments and psychomotor activity
assessments
Before drug treatment, all mice were habituated in the testing
environment and mice were injected with a single dose of cocaine
(25 mg/kg, i.p.; Sigma, St. Louis, MO, USA). Horizontal
locomotor activity was monitored for 180 min after drug
administration and analyzed as described previously [9].
3. Glutamate release from striatal synaptosomes
3H-glutamate release experiments were performed as previously
described after purification of striatal nerve terminals using a
sucrose/Percoll fractionation method [22]. Briefly, nerve terminals
were equilibrated at 37uC for 10 min, loaded with 3H-glutamate
(0.2 mM, specific activity of 45 Ci/mmol, Amersham, Piscataway,
NJ, USA) for 5 min at 37uC, washed, layered over Whatman GF/
C filters and superfused with oxygenated Krebs solution for 20
min before starting collection of the superfusate. Synaptosomes
were stimulated with 20 mM K+ at 3 min (S1) and 9 min (S2) after
starting sample collection, triggering a release of tritium that was
mostly 3H-glutamate, released in a Ca2+-dependent manner [22].
The A2AR agonist CGS21680 (Tocris, Bristol, UK), tested at a
concentration that is supra-maximal but selective to activate A2AR
[22], was added 2 min before S2 onwards and its effect was
quantified by modification of the S2/S1 ratio compared to control
chambers. Normalized facilitation by CGS21680 of the K+-evoked
3H-glutamate release was tested by the one-sample t-test against
the hypothetical value of 0% compared to paired control
experiments carried out in the same batch of nerve terminals in
the absence of added drugs. P # 0.05 was considered to represent
a significant difference.
4. Immunocytochemical detection of A2AR in
glutamatergic and GABAergic nerve terminals
Striatal nerve terminals were purified through a discontinuous
Percoll gradient and platted over poly-L-lysine-coated cover-slips
for immunocytochemical analysis, using antibodies that were
previously validated [22,50]. Permeabilized nerve terminals were
incubated for 1 hour with rabbit anti-A2AR (1:500, Upstate
Biotechnology, Lake Placid, NY, USA), and guinea pig anti-
vesicular GABA transporters (vGAT, 1:1,000, Calbiochem, San
Diego, CA, USA) or guinea pig anti-vesicular glutamate type 1
transporters (vGluT1, 1:1000, Chemicon, Temecula, CA, USA)
antibodies followed by a 1 hour incubation with different
AlexaFluor-labeled secondary antibodies (1:2,000, Molecular
Probes, Leiden, The Netherlands), which did not yield any signal
in the absence of the corresponding primary antibodies. After
washing and mounting onto slides with Prolong Gold Antifading
(Invitrogen, Eugene, OR, USA), preparations were visualized in a
Zeiss fluorescence microscope and analyzed with MetaFluor 5.0.
Each coverslip was analyzed by counting three different fields and
in each field a total amount of 150 individualized elements
excluding elements based on their insufficient or excessive pixel
intensity and excessive size, as previously described [22,50]. Note
that this approach can only globally distinguish glutamatergic from
GABAergic terminals, but the anti-vGluT1 and anti-vGAT
antibodies used cannot distinguish between the different types of
glutamatergic terminals (projecting to the direct or indirect
pathways) or GABAergic terminals (direct projections or collater-
als).
5. Western blot analysis of DARPP-32 phosphorylation at
Thr-32 and Thr-75
DARPP-32 immunoreactivity was analyzed as previously
described [51] with modifications. Mice were sacrificed by
decapitation (45 min after i.p. injection of vehicle or drug) and
their heads were immediately immersed in liquid nitrogen for 6
sec. The striata were rapidly (within 20 sec) dissected out on an ice-
cold surface, sonicated in 750 mL of 2% sodium dodecylsulfate,
and boiled for 10 min. After protein determination, 30 mg protein
from each sample was loaded and separated by Western blot to
quantify phospho-DARPP-32 (Thr34) (1:1000, antibody kindly
provided by Dr. Greengard) and phospho-DARPP-32 (Thr75)
(1:1,000, Cell Signaling, Danvers, MA, USA), normalized to total
DARPP-32 immunoreactivity (1:1,000, Cell Signaling).
6. Immunohistochemistry of c-Fos expression and double
labeling of c-Fos with dynorphin or enkephalin
Sequential antibody detection of c-Fos and dynorphin.
Free-floating brain coronal sections (30 mm) were double stained
immunohistochemically with anti-c-Fos and anti-dynorphin poly-
clonal antibodies using standard avidin–biotin procedures follow-
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ing a sequential antibody detection protocol as described
previously [52,53]. For this procedure, the first antibody, i.e., a
goat anti-dynorphin polyclonal antibody (1:200, sc-46313, Santa
Cruz, CA, USA) was detected first, using immunoperoxidase
staining enhanced with 0.08% nickel ammonium sulfate, which
yields a dark grayish color. After completion of the first staining,
the same sections were incubated with an avidin/biotin blocking
solution in order to block free avidin/biotine sites from the first
biotinylated goat anti-rabbit IgG antibody. Then, sections were
processed for immunolabeling with the second primary antibody,
i.e., a rabbit anti-c-Fos polyclonal antibody (1:5,000, PC-38,
Calbiochem) following standard protocols using DAB, yielding a
bright brown color. This method has been repeatedly shown to
lack cross-labeling [52,53]. Moreover, the nuclear localization of c-
Fos staining, as opposed to the cytoplasm/neuropil staining of
dynorphin, makes it easy to differentiate the two types of staining.
Fluorescence double immunohistochemistry of c-Fos
and enkephalin. Coronal brain sections (30 mm) were double
stained overnight with primary antibodies, namely rabbit anti-c-
Fos polyclonal antibody (1:5,000, PC-38, Calbiochem) and mouse
anti-enkephalin monoclonal antibody (1:50, sc-47705, Santa
Cruz). After washing, slices were incubated for 1 hour at room
temperature in a solution containing a goat anti-rabbit secondary
antibody, conjugated to Cy3 (1:750, 111-165-144, Jackson
Immuno Research, West Grove, PA, USA) and a goat anti-mouse
secondary antibody, conjugated to FITC (1:200, 115-095-166,
Jackson Immuno Research). The sections were then washed 3
times and mounted on gelatin-coated slides and cover slipped with
Vectashield fluorescent mounting medium with DAPI (H-1200,
Vector Lab, Burlingame, CA, USA).
7. Statistical analysis
Statistical comparisons between st-A2AR KO vs st-WT or fb-
A2AR KO vs fb-WT were analyzed (independently for their
different genetic backgrounds) using a paired or unpaired
Student’s t test, according to the experimental design. To
determine the effect of genotype, drug treatment and their
interaction, we applied a two-way ANOVA for repeated
measurements followed by Bonferroni post hoc comparison.
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